Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Stem Cell Therapy Ameliorates Ischemia-reperfusion Induced Kidney Injury After 24 Hours Reperfusion.

Hafazeh L., Changizi-Ashtiyani S., Ghasemi F., Najafi H., Babaei S., Haghverdi F.

Animal Study on Acute Kidney Injury, published in Iran J Kidney Dis (2019) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Iran J Kidney Dis (2019)
Country
Iran
Reported sample size
—
Source database
PubMed
PMID
31880584
Citations
3

Abstract (original English)

The mortality rate in patients with acute kidney injury (AKI) is high. The aim of this study was to evaluate the efficacy of treatment with adipose-derived mesenchymal stem cells (AD-MSC) in renal ischemia-reperfusion (I/R) model in rats. In this study 28 male Wistar rats were divided into four groups of control, sham, I/R24h+PBS, and I/R24h+AD-MSC. Blocking the renal arteries for 45 minutes induced renal I/R and then reperfusion was conducted for 24 hours. Parameters including urine volume, osmolarity, plasma creatinine (Crp), and blood urea nitrogen (BUN) were evaluated and values of creatinine clearance (CCr), absolute sodium excretion (UNaV°), fractional excretion of sodium (FENa), absolute potassium excretion (UKV°) and fractional excretion of potassium (FEK) were calculated. The right kidney was removed to measure the malondialdehyde (MDA) and ferric reducing antioxidant power (FRAP), as well as the left kidney for histological evaluation. I/R caused a significant increase in Crp, BUN, UNaV°, FENa, FEK, MDA, and tissue damages. In addition, the values of CCr, urine osmolarity, and FRAP level decreased significantly (P < .05). Following AD-MSC treatment, values of FENa, Crp, FEK, MDA, and tissue damages decreased significantly, while urine osmolarity increased significantly in the I/R24h + AD-MSC group compared to the I/R24h + PBS group. Furthermore, FRAP values increased

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Acute Kidney InjuryAnimalsAntioxidantsBlood Urea NitrogenCreatinineDisease Models, AnimalKidneyKidney Function TestsMaleMalondialdehyde

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research